Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCIB2
- Development stage
- Unknown
- Lead developer
- Scancell Holdings
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
**SCIB2** is a DNA-based cancer vaccine from Scancell's ImmunoBody platform, designed as a fusion protein encoding a human IgG1 antibody with 16 NY-ESO-1 epitopes incorporated into its CDR regions to target over 80% of HLA phenotypes. It enhances uptake and presentation of the NY-ESO-1 cancer-testis antigen by antigen-presenting cells, inducing high-frequency, high-avidity CD4+ and CD8+ T cell responses that demonstrate potent cytotoxicity against NY-ESO-1-expressing tumor cells. Preclinical studies in mice showed SCIB2 monotherapy achieving 35% long-term survival in established B16-NY-ESO-1 tumors, with enhanced efficacy (up to 100% survival) in combinations with Treg depletion, CTLA-4 blockade, or PD-1 blockade; it outperforms peptide vaccines in T cell avidity and tumor control. Developed by Scancell for solid tumors like NSCLC, melanoma, ovarian, and prostate cancers, with planned nanoparticle delivery in Phase 1/2 trials.[1][2][3][4]
- Other names
- SCIB-6SCIB6SCIB 6
02
Targets
New York esophageal squamous cell carcinoma 1 (NY-ESO-1) peptide-Major Histocompatibility Complex (MHC)NY-ESO-1 (New york esophageal squamous cell carcinoma 1)
Beyond the preview
Go deeper on SCIB2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCIB2.